The 1,3,4-oxadiazole skeleton is of considerable interest due to a wide range of biological and pharmacological activities and has been generally recognized as a privileged structure in medicinal chemistry.^[@ref1]^ It has been shown to lower lipophilicity and increase water solubility when introduced into a structure. Oxadiazoles are known as bioisosteres of amides and esters with often superior hydrolytic and metabolic stability, improved pharmacokinetics, and in vivo performance.^[@ref2]^ Interestingly, oxadiazole peptidic macrocycles showed significantly higher cell membrane pentration compared to their amide congeners.^[@ref3]^ They show widespread applications in pharmaceutical chemistry and material science.^[@ref4]^ Raltegravir,^[@ref5]^ an antiretroviral drug containing the 1,3,4-oxadiazole moiety for the treatment of HIV infection, is marketed. Several compounds ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A) are in late-stage clinical trials, including furamizole as an antibiotic agent,^[@ref6]^ tiodazosin^[@ref7]^ and nesadipil^[@ref8]^ for the treatment of hypertension, and zibotentan as an anticancer agent.^[@ref9]^

![1,3,4-Oxadiazoles in drugs and synthesis.](ol9b02614_0001){#fig1}

Multicomponent reactions (MCRs) are powerful synthetic tools for the synthesis of complex and diverse molecules in a one-pot fashion from more than two starting materials.^[@ref10]^ MCRs are considered green chemistry by reducing the number of synthetic steps, energy consumption, and waste production.^[@ref11]^ In the field of MCRs, the Ugi reaction was appealing because four components are combined to a single product in a straightforward one-pot reaction.^[@ref12]^ It is well suited for diversity-oriented synthesis applicable in drug discovery and stands out due to its ease of synthetic operation and functional group tolerability.^[@ref13]^

Owing to its great importance in multiple areas, several syntheses of the 1,3,4-oxadiazole scaffold are established, including: (1) oxidative cyclization of *N*-acylhydrazones with various oxidizing reagents,^[@ref14]^ (2) cyclodehydration of 1,2-diacylhydrazines with dehydrated reagents,^[@ref15]^ (3) direct reaction of carboxylic acids or acyl chlorides with acid hydrazides or hydrazines,^[@ref16]^ (4) C--H activation/Cu-mediated arylation of preformed 2-substituted 1,3,4-oxadiazole,^[@ref17]^ (5) electrophilic substitution of 2-substituted-5-(trimethylsilyl)-1,3,4-oxadiazole toward various electrophiles,^[@ref18]^ (6) oxidative cleavage of the C(sp^2^)--H or C(sp)--H bond with subsequent cyclization and deacylation,^[@ref19]^ and (7) the Huisgen 1,3,4-oxadiazole synthesis.^[@ref20]^ Notably, Ramazani et al. described an MCR approach toward oxadiazoles using (*N*-isocyanimino)triphenylphosphorane and a Ugi/aza-Wittig sequence ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}C).^[@ref21]^ Eycken et al. reported a copper-catalyzed direct secondary and tertiary C--H alkylation of azoles through a heteroarene--amine aldehyde/ketone coupling reaction toward 2,5-disubstituted 1,3,4 oxadiazoles ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B).^[@ref22]^ Yudin et al. generated macrocyclic peptides applying Ramazani's method ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}D).^[@ref3]^

However, the existing procedures still involve the use of hazardous or expensive reagents, harsh conditions, long reaction times, lack of structural and functional group diversity, or the requirement of linear assembly of reactants using multistep synthesis. Surprisingly, the Huisgen reaction, which can afford 1,3,4-oxadiazoles by the reaction of 5-substituted 1*H*-tetrazoles with electrophiles (such as carboxylic acid anhydrides or acid chlorides), has received comparatively little interest in the past few years.^[@ref23]^ Compared with other methods, the Huisgen reaction is a facile approach to afford the corresponding 2,5-disubstituted 1,3,4-oxadiazoles in a very clean and efficient manner. The convergent approach toward the synthesis of 1,3,4-oxadiazole derivatives with the flexibility to incorporate various substituent groups at both the 2- and 5-positions is thus highly desirable. Thus, we tried to elaborate a convenient method for constructing diversely 2,5-substituted 1,3,4-oxadiazoles from easily accessible starting materials via Ugi/Huisgen sequence reactions.

To test our hypothesis and design, piperidine **1a** (1 equiv) was reacted with 3-phenylpropanal **2a** (1 equiv), trimethylsilyl azide **3** (1.1 equiv) and *tert*-octyl isocyanide **4** (1.1 equiv) in methanol (room temperature, 12 h) to obtain the Ugi product **5a** in very good yield (85%). Then **5a** was treated with 4 N HCl/dioxane to deprotect the *tert*-octyl group and to give 1-(3-phenyl-1-(1*H*-tetrazol-5 yl)propyl)piperidine **5a′**. This intermediate tetrazole **5a′** was directly dissolved in pyridine (0.5 M) and was treated with 2,6-dichlorobenzoyl chloride **6a** (1.0 equiv) at 100 °C for 6 h. This reaction afforded the desired oxadiazole product (**7aa**) in 30% yield ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 1) and motivated us to optimize the conditions. Regarding the isocyanide component, we chose cleavable isocyanides that are high yielding in the first step of the Ugi tetrazole reaction. After this first successful attempt for the 1,3,4-oxadiazole synthesis, the same procedure was repeated using the *tert*-butyl isocyanide, as an alternative cleavable isocyanide that in theory could result in better atom economy. Although the Ugi tetrazole product was obtained in very good yield, similarly to the previous time, the second step to deprotect the *tert*-butyl group turned out to be much more challenging. Therefore, in the first two reaction steps, the *tert*-octyl isocyanide gave a better outcome and was used in the optimization and investigation of the reaction scope.

###### Optimization Studies for the Formation of **7aa**[a](#t1fn1){ref-type="table-fn"}^,^[b](#t1fn2){ref-type="table-fn"}
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  entry                               2,6-dichloroPhCOCl (equiv)   solvent (v/v)    time (h)   *T* (°C)   yield (%)
  ----------------------------------- ---------------------------- ---------------- ---------- ---------- -----------
  1                                   1.0                          pyr              6          100        30
  2                                   1.2                          pyr              6          100        38
  3                                   1.2                          pyr              8          110        44
  4                                   1.2                          pyr              8          120        50
  5[c](#t1fn3){ref-type="table-fn"}   1.2                          pyr              8          120        45
  **6**                               **1.5**                      **pyr**          **8**      **120**    **75**
  7                                   1.5                          pyr              10         120        70
  8                                   1.5                          pyr              12         120        69
  9                                   2.0                          pyr              8          120        65
  10                                  1.5                          pyr              8          140        61
  11                                  1.5                          pyr              8          160        60
  12                                  1.5                          pyr/MeCN (1:1)   8          120        25
  13                                  1.5                          pyr/MeCN (1:2)   8          120        21
  14                                  1.5                          pyr/MeCN (1:3)   8          120        20

The Ugi reaction was carried out using **1a** (1.0 mmol), **2a** (1.0 mmol), **3** (1.1 mmol), and **4** (1.1 mmol) in MeOH (1 M) for 12 h at rt.

Reaction conditions: **5a′** (0.5 mmol), solvent (1 mL), isolated yields.

Reaction mixture concentration (0.25 M).

Careful variation of conditions and analysis revealed that conversion of the tetrazole was not quantitative. In light of this, the ratio of the reactants **5a′** and **6a** was increased to 1:1.2, which enhanced the yield of **7aa** to 38% ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 2). After prolonging the reaction time to 8 h and increasing the reaction temperature to 110 °C, **7aa** was obtained in 44% yield (entry 3). A higher reaction temperature gave a slightly better yield (entry 4). Increasing the amount of solvent reduced the yield (entry 5). Surprisingly, increasing the amount of **6a** to 1.5 equiv considerably improved the reaction performance (75% yield; entry 6). Increasing the reaction time did not help improve the outcome of the product (entries 7 and 8), which was the same case as increasing the number of equivalents of acyl chloride **6a** (entry 9). However, increasing the temperature to 140 and 160 °C resulted in lower yields (entries 10 and 11). Furthermore, the outcome of the reaction was sharply decreased by applying a mixture of pyridine and acetonitrile as cosolvents in different ratios (entries 12--14). Thus, the best conditions for the Huisgen reaction were determined to be 1.0 equiv of 5-substituted-1*H*-tetrazole and 1.5 equiv of acyl chloride in 0.5 M of pyridine at 120 °C for 8 h.

With the optimized conditions in hand, a series of Ugi products (**5a**--**5m**) were synthesized in good to excellent yield and were used to explore the scope and limitations of the Huisgen reaction by reacting diverse secondary amines with different aldehydes/ketones, *tert*-octyl isocyanide, and TMSN~3~ in methanol followed by deprotection and Huisgen rearrangement to furnish the corresponding library **7a**--**m** ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). Surprisingly, all of the substrates **1**, **2**, **3**, **4**, and **6** led to the expected 1,3,4-oxadiazole products **7a**--**m** in 39--80% yields via three steps, almost irrespective of the electronic and steric factors of the substituents present, indicating great functional group tolerance. As shown in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, various aliphatic aldehydes including 3-phenylpropanal, formaldehyde, 2-phenylacetaldehyde, 3-methylbutanal, isobutyraldehyde, 2-methylbutanal, cyclopentanecarbaldehyde, and 3-(methylthio)propanal proceeded well in this MCR and Huisgen reaction, which is not easily achieved in reported work.^[@ref3],[@ref21],[@ref22]^ An aromatic aldehyde with a substituted group chloro was tolerated (**7d**), and heterocyclic aldehyde with the scaffold of pyridine was compatible in this process to deliver the products in good yields (**7k**).

![Synthesis of 2,5-Disubstituted 1,3,4-Oxadiazoles **7**--\
The amine, aldehyde, azide, isocyanide, and aryl chloride components are depicted with blue, red, brown, green, and pink color, respectively.\
The Ugi reaction was carried out using **1** (1.0 mmol), **2** (1.0 mmol), **3** (1.1 mmol), and **4** (1.1 mmol) in MeOH (1 M) for 12h at rt.\
Reaction conditions: **5** (0.5 mmol), 4 N HCl/dioxane (1 mL), 120 °C, 6 h; then **6** (0.75 mmol), pyridine (1 mL), 120 °C, 8 h.\
Yield refers to the purified products.](ol9b02614_0003){#sch1}

Meanwhile, a variety of secondary amines were also subjected to this process. Interesting moieties often used to enhance water solubility of compounds, such as piperidine, 1-methylpiperazine, morpholine, thiomorpholine, and pyrrolidine, participate in this MCR smoothly to produce the products in moderate to good yields (**7a**--**f**). Besides, 1-phenylpiperazine containing valuable functional groups such as fluoro, trifluoromethyl, cyano, and methoxy were also applied and gave the corresponding products in good yields (**7g**--**k**). Similarly, 1-benzylpiperazine and 1-benzhydrylpiperazine also furnished the different 1,3,4-oxadiazole products by 58% and 63% yields, respectively. Finally, the scope of aryl chlorides was also tested. These diverse aryl chlorides could well engage in this Ugi/Huisgen sequence reactions to treat with tetrazoles for rapid entry to functionalized 1,3,4-oxadiazoles in moderate to good yields (**7a**--**m**). The fluoro, chloro, iodo, methoxy, ethoxy, and cyano were also compatible, and these functional groups could offer ample opportunity for late-stage derivatization. In addition, benzoyl chloride, isobutyryl chloride, pivaloyl chloride and heterocyclic aryl chloride based on furan were well applicable in this methodology to furnish the corresponding products in good yields (**7l**, **7ab**, **7k**, **7h**).

Compound **7e** has been confirmed by X-ray single-crystal analyses ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} and [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.orglett.9b02614/suppl_file/ol9b02614_si_001.pdf)). Both the 1,3,4-oxadiazole and *p*-chlorophenyl rings are flat and coplanar and form π--π stacking motifs in the crystal ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}).

![X-ray structure of compound **7e** (CCDC 1942923).](ol9b02614_0002){#fig2}

Furthermore, the scalability of this method was investigated ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}A). A four-component reaction of amine **1m**, aldehyde **2m**, TMSN~3~**3**, and *tert*-octyl isocyanide **4** was conducted in 10 mmol scale, further reacting with 4-cyanobenzoyl chloride, while the 1,3,4-oxadiazole product **7m** could be obtained in 45% yield (2.3 g). Lastly, we showed several synthetic applications of the herein described oxadiazoles. Product **7ca** was reacted with sodium azide to afford tetrazole **8**, which was further treated with 2,6-dichlorobenzoyl chloride to deliver unsymmetrical bis-oxadiazole **9** ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}B). In another application, the iodo group of **7cb** was coupled with (4-fluorophenyl)boronic acid to give the derivate **10** by a Suzuki reaction ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}C).

![Gram-Scale Reaction and Synthetic Application](ol9b02614_0004){#sch2}

A plausible mechanism is shown in [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}. The deprotection of the *tert*-octyl group under acidic condition gives the monosubstituted tetrazole (intermediate **A**), which is *N*-acylated by the corresponding acyl chloride (intermediate **C**). The unstable *N*-acylated tetrazole undergoes the Huisgen rearrangement with nitrogen elimination, ring-opening (intermediate **D**), and final cyclization toward the 1,3,4-oxadiazole (**7**).

![Proposed Reaction Mechanism](ol9b02614_0005){#sch3}

In summary, an MCR-based synthesis of 2-fold substituted 1,3,4-oxadiazoles has been developed. Considering the importance of 1,3,4-oxadiazole derivatives in natural products and drug discovery, this method provides simple and distinct access to these molecules from rapidly accessible starting materials. Diversity can be achieved through the secondary amine, the aldehyde, and the aryl chloride components. This protocol offers a rapid approach to the 1,3,4-oxadiazole scaffold, along with the achievement of remarkable structural diversity and brevity. The process uses readily available starting materials and simple operation, provides good scalability, and will therefore become a synthetical useful method in organic synthesis and medicinal chemistry.
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